SpringerLink
Log in

The Management of Multiple Drug-Resistant Tuberculosis

  • Chapter
Management of Multiple Drug-Resistant Infections

Part of the book series: Infectious Disease ((ID))

  • 138 Accesses

Abstract

Tuberculosis (TB) will not go away. The decline that has occurred in rates in high-income countries because of chemotherapy (1) has now been reversed; TB remains the leading cause of death worldwide. Between 1998 and 2030, there are expected to be 225 million new cases of TB and 79 million deaths attributable to the disease (2). It is inevitable that the number of drug-resistant cases will also increase. This has serious implications for TB control, especially in low-income countries (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Harris HW. Chemotherapy of tuberculosis: the beginning. In: Rom WN, Garay SM (eds.). Tuberculosis. Boston, MA: Little Brown, 1996, pp. 745 - 749.

    Google Scholar 

  2. Murray C, Saloman JA. Modelling the impact of global tuberculosis strategies. Proc Natl Acad Sci U S A 1998; 95:13, 881-13, 886.

    Google Scholar 

  3. Snider DE, Castro DK. The global threat of drug-resistant tuberculosis. N Engl J Med 1998; 338: 1689 - 1690.

    Article  PubMed  Google Scholar 

  4. World Health Organization. IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World. Report no. 2. Prevalence and Trends (2000). Geneva: World Health Organization, 2000. Publication No. WHO/CDS/TB/2000. 278. Geneva, Communicable Diseases.

    Google Scholar 

  5. Espinal MA, Laszlo A, Simenson L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294 - 1303.

    Article  PubMed  CAS  Google Scholar 

  6. Pablos-Mendez A, Lazlo A, Bustreo F. Anti-tuberculosis Drug Resistance in the World. Geneva, Switzerland: World Health Organization, 1997. WHO/GTP/97.229.

    Google Scholar 

  7. Crofton J, Chaulet P, Maher D. Guidelines for the Management of Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization, 1997. WHO/TB 96.210 (Rev. 1).

    Google Scholar 

  8. Yew W. Directly observed therapy, short course: the best way to prevent MDR-TB. Chemotherapy 1999; 45 (suppl. 12): 26 - 33.

    Article  PubMed  CAS  Google Scholar 

  9. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 1993; 328: 521 - 526.

    Article  Google Scholar 

  10. Lambregts-van Weezenbeek CSB, Veen J. Control of drug resistant tuberculosis. Tuber Lung Dis 1995; 76: 455 - 459.

    Article  Google Scholar 

  11. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, and Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. N Engl J Med 1993; 328: 527 - 532.

    Article  PubMed  CAS  Google Scholar 

  12. Fament-Sailloue M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug resistant tuberculosis in France. A nationwide case-cohort study. Am J Resp Crit Care Med 1999; 160: 587 - 593.

    Google Scholar 

  13. Pitchenik AE, Burr J, Laufer M, et al. Outbreak of drug-resistant tuberculosis at an AIDS centre. Lancet 1990; 336: 440 - 441.

    Article  PubMed  CAS  Google Scholar 

  14. Van Rie A, Gie RP, Enarson D, Beyers N. The outcome of MDR-TB patients in an urban area of South Africa. Int J Tuberc Lung Dis 1999; 3 (suppl. 1): s84 - s85.

    Google Scholar 

  15. Fischi MA, Daikos GL, Uttamchandani RB, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug resistant bacilli. Ann Intern Med 1992; 117: 184 - 190.

    Google Scholar 

  16. Portaels F, Rigouts L, Bastian I. Addressing multi-drug resistant tuberculosis in penitentiary hospitals and the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999; 3: 582 - 588.

    PubMed  CAS  Google Scholar 

  17. Pfyffer GE, Sraessle A, van Gorkum T, et al. Multidrug-resistant tuberculosis in prison inmates, Azerbhaijan. Emerg Infect Dis 2001; 7: 855 - 861.

    PubMed  CAS  Google Scholar 

  18. Hannan MM, Peres H, Maltez F, et al. Investigation and control of a large outbreak of multi-drug resistant tuberculosis at a central Lisbon hospital. J Hosp Infect 2001; 72: 91 - 97.

    Article  Google Scholar 

  19. Moro ML, Errante I, Infuso A, et al. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. Int J Tuberc Lung Dis 2000; 41: 61 - 68.

    Google Scholar 

  20. Breathnach AS, De Ruiter A, Holdsworth GM, et al. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect 1998; 92: 111 - 117.

    Article  Google Scholar 

  21. Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiological and restriction fragment length polymorphism analysis. J Infect 1993; 1684: 1052 - 1055.

    Google Scholar 

  22. Centers for Disease Control and Prevention. Outbreak of multidrug-resistant tuberculosis at a hospital-New York City, 1991. MMWR Morb Mortal Wkly Rep 1993; 4222: 427, 433 - 434.

    Google Scholar 

  23. Pozniak A. Multidrug-resistant tuberculosis and HIV infection. Ann N Y Acad Sci 2001; 953: 192 - 198.

    Article  PubMed  CAS  Google Scholar 

  24. Frieden TR, Sherman LF, Lay Maw K, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis. JAMA 1996; 276: 1229 - 1235.

    CAS  Google Scholar 

  25. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis drug resistance, 1994-1997. N Engl J Med 1998; 344: 1294 - 1303.

    Google Scholar 

  26. Djuretic T, Herbert J, Drobniewski F, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 2002; 57: 477 - 482.

    Article  PubMed  CAS  Google Scholar 

  27. Ormerod P. Tuberculosis and immigration. Br J Hosp Med 1996; 56: 209.

    PubMed  CAS  Google Scholar 

  28. McCarthy OR. Asian immigrant tuberculosis: the effect of visiting Asia. Br J Dis Chest 1984; 78: 248 - 253.

    Article  PubMed  CAS  Google Scholar 

  29. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations. Thorax 1998; 53: 536 - 548.

    Article  Google Scholar 

  30. American Thoracic Society. Treatment of tuberculosis and tuberculosis infections in adults and children. Am J Respir Crit Care Med 1994; 149: 1359 - 1374.

    Google Scholar 

  31. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Resp Dis 1987; 136: 1339 - 1342.

    Article  Google Scholar 

  32. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. 2nd ed, Geneva, Switzerland: WHO, 1997. WHO/TB/97.220.

    Google Scholar 

  33. Hayward AC, Bennett DE, Herbert J, et al. Risk factors for drug resistance in patients with tuberculosis in England and Wales 1993-1994. Thorax 1996; 51 (suppl. 3): S32.

    Google Scholar 

  34. Harries AD, Maher D, Muula B, Nyangula D. An audit of HIV serostatus in tuberculosis patients, Blantyre, Malawi. Tuber Lung Dis 1995; 76: 413 - 417.

    Article  PubMed  CAS  Google Scholar 

  35. Espinal MA, Laserson K, Comacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 10: 887 - 893.

    Google Scholar 

  36. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521 - 526.

    Article  PubMed  CAS  Google Scholar 

  37. Caws M, Drobniewski FA. Molecular techniques in the diagnosis of Mycobacterium tuberculosis and the detection of resistance. Ann N Y Acad Sci 2001; 953: 138 - 145.

    Article  PubMed  CAS  Google Scholar 

  38. Telenti A, Imboden P, Marchesi F. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647 - 649.

    Article  PubMed  CAS  Google Scholar 

  39. Quemard AJC, Sacchetini A, Dessen C, et al. Enzymatic characterization of the target for isonization in Mycobacterium tuberculosis. Biochemistry 1995; 34: 8235 - 8241.

    Article  PubMed  CAS  Google Scholar 

  40. Telenti A, Marchesi F, Balz M. Rapid identification of Mycobacteria to species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 1993; 31: 175 - 178.

    PubMed  CAS  Google Scholar 

  41. Rossaur R, Traore H, De Beenhouwer H, et al. Evaluation of INNO-Lipa Rif. TB assay, a reverse hybridisation assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 1997; 41: 2093 - 2098.

    Google Scholar 

  42. Carriere C, Riska PF, Zimhony O, et al. Conditionally replicating luciferase reporter phages: improved sensitivity for rapid detection and assessment of drug susceptibility of Mycobacterium tuberculosis. J Clin Microbiol 1997; 35: 3232 - 3239.

    PubMed  CAS  Google Scholar 

  43. Drobniewski FA, Watterson SA, Wilson SM, Harris GS. A clinical, microbiological and economic analysis of a national service for the rapid diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis. J Med Microbiol 2000; 49: 271 - 278.

    PubMed  CAS  Google Scholar 

  44. Costello HD, Cras GJ, Snider DE Jr. Drug resistance among previously treated tuberculosis patients, a brief report. Am Rev Respir Dis 1980; 121: 313 - 316.

    PubMed  CAS  Google Scholar 

  45. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784 - 791.

    Article  PubMed  CAS  Google Scholar 

  46. Heifets LB, Lindhom-Levy PJ. Bacteriostatic and bacteriocidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium-complex. Tubercle 1987; 68: 267 - 276.

    Article  PubMed  CAS  Google Scholar 

  47. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medication by patients with AIDS. N Engl J Med 1992; 327: 1817 - 1818.

    Article  PubMed  CAS  Google Scholar 

  48. Ormerod P. The clinical management of the drug-resistant patient. Ann N Y Acad Sci 2001; 953: 185 - 191.

    Article  PubMed  CAS  Google Scholar 

  49. Tsukumara M. Antituberculosis activity of ofloxacin (DL8280) on experimental tuberculosis in mice. Am Rev Respir Dis 1985; 132: 915.

    Google Scholar 

  50. Marentra KN. Quinolones and multidrug-resistant tuberculosis. Chemotherapy 1999; 45 (suppl. 2): 12 - 18.

    Article  Google Scholar 

  51. Mangunnegoro H, Hudoyo A. Efficacy of low-dose ofloxacin in the treatment of multidrugresistant tuberculosis in Indonesia. Chemotherapy 1999; 45 (suppl. 2): 19 - 25.

    Article  PubMed  CAS  Google Scholar 

  52. Peloquin C. Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci 2001; 93: 157 - 163.

    Article  Google Scholar 

  53. Rodriguez JC, Ruiz M, and Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin, and linezolid against mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464 - 467.

    Article  PubMed  CAS  Google Scholar 

  54. Nadler JP, Berger J, Nord JA, Cofsky R, and Saxena, M. Amoxycillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025 - 1026.

    Article  PubMed  CAS  Google Scholar 

  55. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetezone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 337: 627 - 630.

    Article  PubMed  CAS  Google Scholar 

  56. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multi-drug resistant tuberculosis. Eur Respir J 2002; 20 (suppl. 36): 66s - 77s.

    Article  Google Scholar 

  57. Muthuswamy P, Chechani V, Barker W. Surgical management of pulmonary tuberculosis. Am Rev Respir Dis 1992; 145 (suppl. 4): A816.

    Google Scholar 

  58. Van Leuven M, de Groot M, Shean K, von Oppellum, and Wilcox PA. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann Thorac Surg 1997; 63: 1368 - 1373.

    Article  PubMed  Google Scholar 

  59. Chiang CY, Yu MC, Bai KL, Suo J, Lin TP, and Lee YC. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int J Tuberc Lung Dis 2001; 5: 272 - 277.

    PubMed  CAS  Google Scholar 

  60. Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 121: 448 - 453.

    Article  PubMed  CAS  Google Scholar 

  61. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170 - 174.

    Article  PubMed  CAS  Google Scholar 

  62. Turett GS, Telzak EE, Torian VL, et al. Improved outcomes for patients with multidrugresistant tuberculosis. Clin Infect Dis 1995; 21: 1238 - 1244.

    Article  PubMed  CAS  Google Scholar 

  63. Amaral L, Kristiansen JE, Viveros M, and Antouguia J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J Antimicrob Chemother 2001; 47: 505 - 511.

    Article  PubMed  CAS  Google Scholar 

  64. Stanford JL, Stanford CA, Grange JM, Lan NN, and Gtemadi A. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug resistant pulmonary tuberculosis? Respir Med 2001; 95: 435 - 436.

    Article  Google Scholar 

  65. Holland SM. Cytokine therapy of mycobacterial infections. Adv Intern Med 2001; 45: 505511.

    Google Scholar 

  66. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother 1997; 40: 319 - 327.

    Article  PubMed  CAS  Google Scholar 

  67. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000. Thorax 2000; 55: 887 - 901.

    Article  Google Scholar 

  68. Dillon J, Dickinson JM, Sole K, et al. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampicin, isoniazid and pyrazinamide. Antimicrob Agents Chemother 1996; 40: 552 - 555.

    Google Scholar 

  69. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786 - 792.

    Article  PubMed  CAS  Google Scholar 

  70. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447 - 2457.

    CAS  Google Scholar 

  71. Gallagher CT, Passannante MR, Reichman LB. Preventive therapy for multi-drug resistant tuberculosis (MDR-TB): a Delphi survey. Am Rev Respir Dis 1992; 145 (suppl.): A812.

    Google Scholar 

  72. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992; 41: 61 - 71.

    Google Scholar 

  73. Moore-Gillon J. Multidrug-resistant tuberculosis-this is the cost. Ann N Y Acad Sci 2001; 953: 233 - 240.

    Article  PubMed  CAS  Google Scholar 

  74. Rajeswari R, Balasubramanian R, Muniyandi M, Geetharamanis Theresa X, and Venkatasan P. Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis 1999; 3: 869 - 877.

    PubMed  CAS  Google Scholar 

  75. Kamolratanaku P, Sawert H, Kongsin S, et al. Economic impact of tuberculosis at the household level. Int J Tuberc Lung Dis 1999; 3: 596 - 602.

    Google Scholar 

  76. White VLC, Moore-Gillon J. Resource implications of multidrug-resistant tuberculosis. Thorax 2000; 55: 962 - 963.

    Article  PubMed  CAS  Google Scholar 

  77. NHS. Tuberculosis Control in London-the Need for a Change. NHS Executive, December 1998. (NT 980004).

    Google Scholar 

  78. World Health Organization. Tuberculosis Programme: Framework for Effective Tuberculosis Control. Geneva, Switzerland: World Health Organisation, 1994. WHO/TB/94.179.

    Google Scholar 

  79. Farmer PE, Kim JY. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus, " BMJ 1998; 317: 671 - 674.

    CAS  Google Scholar 

  80. Park SK, Kim CT, Sond SD. Outcome of therapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. Int J Tuberc Lung Dis 1998; 2: 877 - 884.

    PubMed  CAS  Google Scholar 

  81. Farmer P. The dilemma of MDRTB in the global era. Int J Tuberc Lung Dis 1998; 2: 869 - 876.

    PubMed  CAS  Google Scholar 

  82. Bastian I, Rigouts A, Van Deun A, Porteals F. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull WHO 2000; 78: 238 - 251.

    PubMed  CAS  Google Scholar 

  83. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980 - 1989.

    Article  PubMed  Google Scholar 

  84. Public Health (Control of Disease) Act 1984, §35,37,38.

    Google Scholar 

Download references

Authors
  1. Sanjay Bhagani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Lipman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Microbiology, Royal Free and University College Medical School, London, England

    Stephen H. Gillespie MD, FRCP, FRCPath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bhagani, S., Lipman, M. (2004). The Management of Multiple Drug-Resistant Tuberculosis. In: Gillespie, S.H. (eds) Management of Multiple Drug-Resistant Infections. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-738-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-738-3_14

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-438-8

  • Online ISBN: 978-1-59259-738-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation